# A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence

> **NCT02382276** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 405 (actual)

## Conditions studied

- Alcohol Dependence

## Interventions

- **DRUG:** Nalmefene hydrochloride

## Key facts

- **NCT ID:** NCT02382276
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-13
- **Primary completion:** 2017-01-18
- **Final completion:** 2017-01-18
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2020-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02382276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02382276, "A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02382276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*